Display options
Cite
Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013;6:131-9doi: 10.2147/DMSO.S43403.
Shin, J. H., & Gadde, K. M. (2013). Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes, metabolic syndrome and obesity : targets and therapy, 6131-9. https://doi.org/10.2147/DMSO.S43403
Shin, Jin Hee, and Gadde, Kishore M. "Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 6 (2013): 131-9. doi: https://doi.org/10.2147/DMSO.S43403
Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013 Apr 08;6:131-9. doi: 10.2147/DMSO.S43403. Print 2013. PMID: 23630428; PMCID: PMC3626409.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Syndr Obes. 2013 Apr 08;6:131-9. doi: 10.2147/DMSO.S43403. Print 2013.

Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.

Diabetes, metabolic syndrome and obesity : targets and therapy

Jin Hee Shin, Kishore M Gadde

Affiliations

  1. Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.

PMID: 23630428 PMCID: PMC3626409 DOI: 10.2147/DMSO.S43403

Abstract

Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications - seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.

Keywords: Qsymia; antiobesity drugs; combination drug; obesity; phentermine; topiramate; weight loss

References

  1. Diabetes Obes Metab. 2007 May;9(3):360-8 - PubMed
  2. Epilepsy Res. 2011 Aug;95(3):189-99 - PubMed
  3. J Clin Invest. 2006 Jul;116(7):1784-92 - PubMed
  4. Curr Drug Saf. 2009 Jan;4(1):2-4 - PubMed
  5. Epilepsia. 2000;41(S1):35-9 - PubMed
  6. BMJ. 2010 Feb 09;340:c824 - PubMed
  7. Obes Res. 2003 Jun;11(6):722-33 - PubMed
  8. Am J Psychiatry. 2003 Feb;160(2):255-61 - PubMed
  9. Obes Rev. 2000 Oct;1(2):113-9 - PubMed
  10. Arch Intern Med. 2012 Nov 12;172(20):1557-64 - PubMed
  11. Brain Res. 2009 Mar 25;1262:16-24 - PubMed
  12. Neuropsychopharmacology. 2003 Jul;28(7):1292-9 - PubMed
  13. J Intern Med. 2008 Apr;263(4):336-52 - PubMed
  14. Curr Pharm Des. 2008;14(7):655-60 - PubMed
  15. JAMA. 2004 Feb 4;291(5):605-14 - PubMed
  16. Obes Res. 2000 Dec;8(9):656-63 - PubMed
  17. Lancet. 2011 Apr 16;377(9774):1341-52 - PubMed
  18. Am J Physiol Endocrinol Metab. 2005 Mar;288(3):E617-24 - PubMed
  19. Acta Ophthalmol (Copenh). 1984 Oct;62(5):739-45 - PubMed
  20. Prim Care. 2009 Jun;36(2):407-15 - PubMed
  21. JAMA. 1996 Dec 18;276(23):1907-15 - PubMed
  22. Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410 - PubMed
  23. Am J Hypertens. 1999 Feb;12(2 Pt 2):50S-55S - PubMed
  24. Obes Res. 2004 Oct;12(10):1658-69 - PubMed
  25. Synapse. 2005 May;56(2):94-9 - PubMed
  26. Clin Pharmacokinet. 2004;43(12):763-80 - PubMed
  27. Sleep. 2012 Nov 01;35(11):1529-39 - PubMed
  28. Int J Obes. 1989;13 Suppl 2:39-46 - PubMed
  29. Obes Res. 2003 Apr;11(4):556-62 - PubMed
  30. Am J Cardiol. 2005 Jul 15;96(2):243-51 - PubMed
  31. Am J Clin Nutr. 2012 Feb;95(2):297-308 - PubMed
  32. Lancet. 2005 Oct 1;366(9492):1197-209 - PubMed
  33. Obesity (Silver Spring). 2012 Feb;20(2):330-42 - PubMed
  34. Circulation. 2006 Aug 29;114(9):974-84 - PubMed
  35. Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):353-8 - PubMed
  36. Diabetes Care. 2007 Jun;30(6):1480-6 - PubMed
  37. Neurology. 2008 Jul 22;71(4):272-6 - PubMed
  38. Ann Intern Med. 2011 Oct 4;155(7):434-47 - PubMed
  39. Int J Obes. 1989;13(2):123-36 - PubMed
  40. Pharmacotherapy. 2006 Mar;26(3):375-87 - PubMed
  41. Arch Intern Med. 2000 Apr 10;160(7):898-904 - PubMed
  42. Nutrition. 2000 Oct;16(10):961-6 - PubMed
  43. Int J Obes (Lond). 2007 Jul;31(7):1140-7 - PubMed
  44. Expert Opin Pharmacother. 2009 Apr;10(6):921-5 - PubMed
  45. Eur J Clin Pharmacol. 2007 Sep;63(9):891-2; author reply 893 - PubMed
  46. Int J Obes (Lond). 2007 Jan;31(1):138-46 - PubMed
  47. Am J Ther. 2009 Jul-Aug;16(4):354-64 - PubMed
  48. J Behav Med. 1981 Jun;4(2):159-74 - PubMed
  49. Ann Intern Med. 1993 Oct 1;119(7 Pt 2):764-70 - PubMed
  50. Eur J Clin Pharmacol. 2007 Feb;63(2):123-34 - PubMed
  51. Int J Obes Relat Metab Disord. 2002 Mar;26(3):344-53 - PubMed

Publication Types